Brian Andrew Jonas, M.D., Ph.D.

Education

M.D., UC Davis School of Medicine, Davis CA 2007

Ph.D., Biochemistry and Molecular Biology, UC Davis School of Medicine, Davis CA 2007

B.A., UC Berkeley, Berkeley CA 1999

Internship: Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2007-2008

Residency

Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2008-2009

Fellowships

Hematology and Oncology, Stanford University School of Medicine, Stanford CA 2009-2013

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Hematology,

Drug Enforcement Administration Registration,

Medical Board of California-Physician and Surgeon license,

Professional Memberships

American Association for Cancer Research

American College of Physicians

American Medical Association

American Physician-Scientist Association

American Society of Clinical Oncology Associate Member

American Society of Hematology

Association of Northern California Oncologists (ANCO)

California Cancer Consortium

California Medical Association

Myelodysplastic Syndrome Foundation

Southwest Oncology Group (SWOG)

UC Hematologic Malignancies Consortium

Honors and Awards

Internal Medicine Outstanding Clinician Award, UC Davis Department of Internal Medicine, 2020

Highest Accrual, Hematologic Malignancies Clinical Trials, UC Davis Comprehensive Cancer Center, 2015, 2016, 2017, 2018, 2019, 2020

Elected to Fellow in the American College of Physicians (FACP), 2019

Named Sacramento Magazine Top Doctor Hematology/Oncology, 2018, 2019

Named to M3814 CTEP/NCI Project Team, 2018

Named to Pevonedistat CTEP/NCI Project Team, 2017

SWOG Leadership Academy Award, 2017

Honored for Founding the WeCARE! Blood Cancer Peer Navigator Program, 2015

K12 Scholar Award, UC Davis Paul Calabresi Clinical Oncology K12 Program, NIH/NCI, 2014, 2015, 2016, 2017

Fellowship Award, Stem Cell Training Program, California Institute for Regenerative Medicine, 2013, 2014

Special Fellow in Clinical Research Award, Leukemia & Lymphoma Society Career Development Program, 2013

Loren D. Carlson Student Research Award, UC Davis School of Medicine, 2007

Allan T. Nunn, MD Memorial Scholarship in Oncology, UC Davis School of Medicine, 2007

Alpha Omega Alpha (AOA), Eta California Chapter, UC Davis, 2006

Phi Sigma Biological Sciences Honor Society, Gamma Delta Chapter, UC Davis, 2004

Physician-Scientist Training Program Fellowship Award, UC Davis School of Medicine, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007

UC Regents Scholarship, UC Davis School of Medicine, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007

Phi Beta Kappa Society, Alpha Chapter, UC Berkeley, 1999

Golden Key Honor Society, UC Berkeley, 1999

Select Recent Publications

For a comprehensive list of Dr. Jonas' publications, please click here

Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):453-458. doi:10.1016/j.clml.2020.02.006. Epub 2020 Feb 20.

Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):E291-E294. doi:10.1002/ajh.25605. Epub 2019 Aug 20.

Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 Dec;33(12):2795-2804. doi:10.1038/s41375-019-0612-8. Epub 2019 Oct 18.

Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1. doi:10.1016/j.clml.2019.05.008. Epub 2019 May 13.

Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 Aug;20:102004. doi:10.1016/j.nano.2019.04.007. Epub 2019 May 2.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2019 Jul;20(7):984-997.

Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019 Jul;94(7):803-811. Published online 2019 May 1. doi:10.1002/ajh.25484.

Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW. Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics. 2019 Jun;7(27):1-22. Published online 2019 May 9. doi:10.3390/toxics7020027.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jun;133(1):7-17. doi:10.1182/blood-2018-08-868752. Epub 2018 Oct 25.

Galkin M, Jonas BA. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core Evid. 2019;14: 3–17. Published online 2019 Apr 26. doi:10.2147/CE.S172912.